Issued Tuesday, the patent covers a method of treatment involving the modulation of drug-drug interactions during treatment with vadadustat. The other 14 patents listed for the drug have expiration dates ranging from 2027 to 2036.
The Food and Drug Administration approved Vafseo in March 2024 to treat anemia due to chronic kidney disease. The drug has been available in the United States since January 2025.



Comments (0)
No comments yet. Be the first!